cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant

Louis, David N ¹ ; Giannini, Caterina ² ; Capper, David ³ ; Paulus, Werner ⁴ ; Figarella-Branger, Dominique ⁵ ; Lopes, M Beatriz ⁶ ; Batchelor, Tracy T ⁷ ; Cairncross, J Gregory ⁸ ; van den Bent, Martin ⁹ ; Wick, Wolfgang ¹⁰ ; Wesseling, Pieter <sup>11 

1</sup>  Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 
²  Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 
³  Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany 
⁴  Institute of Neuropathology, University Hospital Münster, Münster, Germany 
⁵  Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, Hôpital de la Timone, Service d’Anatomie Pathologique et de Neuropathologie, Marseille, France 
⁶  Departments of Pathology and Neurological Surgery, University of Virginia, Charlottesville, VA, USA 
⁷  Departments of Neurology, Radiation Oncology and Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 
⁸  Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada 
⁹  The Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam, The Netherlands 
¹⁰  Neurology Clinic and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany 
¹¹  Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands; Department of Pathology, Princess Máxima Center for Pediatric Oncology, University Medical Center Utrecht, Utrecht, The Netherlands